IBD Market Snapshot: New Medicines Try To Address Patient, Physician Demands
Oral Drugs, Novel Biologics Offer New Options
Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.
